Hand-foot-syndrome is associated with improved survival in patients treated with sorafenib for hepatocellular carcinoma

Introduction: Hepatocellular carcinoma (HCC) is a frequent complication of chronic liver diseases and a leading cause of cancer related deaths. Systemic treatments for HCC like sorafenib might be limited by toxicity and impaired liver function. Clear parameters predicting to the response to sorafenib therapy are sparse. Patients and methods: Single center cohort study of patients suffering from advanced HCC treated with sorafenib at the university hospital Heidelberg, Germany. Data on adverse events, liver function, remission state and survival were recorded. Influence of adverse events on survival was evaluated…